-
MRTX849
- names:
MRTX849
- CAS号:
2326521-71-3
MDL Number: - MF(分子式): C32H35ClFN7O2 MW(分子量): 604.12
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM004293-5mg | 5mg | 98.04% | ¥ 7425.00 | ¥ 7425.00 | 2-3天 | ¥ 0.00 | ||
| YZM004293-1mg | 1mg | 98.04% | ¥ 4550.00 | ¥ 4550.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 2326521-71-3 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C32H35ClFN7O2 |
| 分子量 Molecular Weight | 604.12 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度200 mg/mL(331.06 mM;Need ultrasonic) |
| 性状 | |
| 储藏条件 Storage conditions | -20°C, stored under nitrogen * In solvent : -80°C, 6 months月; -20°C, 1 month月 (stored under nitrogen) |
MRTX849(CAS:2326521-71-3)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | MRTX849 是一种有效的,口服可用,突变选择性的KRAS G12C共价抑制剂,具有潜在抗肿瘤活性的 |
| Introduction | MRTX849 is a potent, orallyvailable, and mutationelective covalent inhibitor of KRAS G12Cwith potential antineoplastic activity. MRTX849 covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDPound conformation, and inhibits KRASependent signal transduction[2]. |
| Application1 | |
| Application2 | |
| Application3 |
MRTX849 是一种有效的,口服可用,突变选择性的KRAS G12C共价抑制剂,具有潜在抗肿瘤活性的。MRTX849 在半胱氨酸 12 残基处与 KRAS G12C 共价结合,将蛋白锁定在非活性的 GDP 结合构象中,并抑制 KRAS 依赖性信号转导。MRTX849 is a potent, orally-available, and mutation-selective covalent inhibitor ofKRAS G12Cwith potential antineoplastic activity. MRTX849 covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2].
【1】.Christensen JG, et al. The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2019 Oct 28. pii: CD-19-1167.
【2】.Kyriakos P. Papadopoulos, et al. A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. Journal of Clinical Oncology 2019 37:15_suppl, TPS3161-TPS3161.
【2】.Kyriakos P. Papadopoulos, et al. A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. Journal of Clinical Oncology 2019 37:15_suppl, TPS3161-TPS3161.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


